Aims: Basal insulin (BI) treatment initiation and dose titration in type 2 diabetes (T2DM) are often delayed. Such "clinical inertia" results in poor glycaemic control and high risk of long-term complications. This survey aimed to determine healthcare professional (HCP) and patient attitudes to BI initiation and titration.
| INTRODUCTION
Basal insulin (BI) therapy is integral to the management of people with type 2 diabetes (T2DM) uncontrolled on oral therapies.
1 BI dose titration is required to optimize treatment. 2 Although insulin titration algorithms have been published, 3, 4 the literature continues to report a significant delay in treatment initiation and intensification in people with T2DM with suboptimal glycaemic control. [5] [6] [7] More than 50% of people with T2DM initiated on insulin therapy do not achieve the recommended HbA1c target (<7.0 %). 8 Failure to achieve glycaemic targets has been shown in several studies, [9] [10] [11] [12] with many patients also being unable to maintain long-term glycaemic control. For example, in a study in the USA, 57% of those who initially achieved glycaemic goals were unable to sustain control over 2.5 years of follow-up. 12 Together these findings indicate that there is a clear unmet need to optimize BI titration in clinical practice.
The delay in BI treatment initiation or dose optimization in individuals not achieving glycaemic targets with their current treatment is often termed clinical inertia and can arise for several reasons. Both patients and healthcare professionals (HCPs) may focus on more immediate issues, such as fear of hypoglycaemia and/or weight gain, which may distract from the need to achieve glycaemic target. 13 HCPs also often have limited time with each patient, and clinical inertia is more frequent when medical appointments are short. 14 Managing the complex care needs of individuals with T2DM may also contribute to clinical inertia; for each additional clinical concern mentioned by a patient with HbA1c >7.0 % during a consultation, it has been reported that the likelihood of their diabetes treatment being intensified at that visit was reduced by 49%. 14 Poor glycaemic control is associated with long-term diabetesrelated macrovascular and microvascular complications, including cardiovascular disease, retinopathy, neuropathy, renal failure, and peripheral vascular disease. 15, 16 The need to reduce delays in BI initiation and improve titration is relevant for people with T2DM newly initiated on BI therapy, as well as people currently on insulin therapy who are not achieving their targets. For patients who may need to intensify their diabetes treatment, insulin titration optimization could delay the need for additional antihyperglycaemic medication, thereby decreasing the burden of treatment. This market research survey was conducted to help understand HCP and patient attitudes to BI therapy titration, in order to identify how barriers to successful titration can be addressed.
| METHODS

| Survey design
An online market research survey of HCPs and patients with T2DM
in the USA, France and Germany was conducted (July-August 2015).
The survey evaluated the current attitudinal and behavioral variables of respondents and took approximately 45 minutes to complete. The survey questions (Tables S1 and S2) were developed by Sanofi with medical expert input, tested online before launch, and validated in English, French, and German. The survey was developed and conducted in line with European Society for Opinion and Marketing
Research (ESOMAR) and European Pharmaceutical Market Research
Association (EphMRA) guidelines. 17, 18 Online informed consent was obtained from each participant before survey completion.
| Survey participants
Participants were recruited by email from existing worldwide panels, 
| Data analysis and statistics
Quality control checks were performed during the data analysis.
Descriptive statistics were used to assess survey responses, with percentages calculated based on the number of responders to the respective questionnaire item. The margin of error was AE5% at the 95% confidence interval, based on the number of HCPs and patients recruited.
3 | RESULTS
| Survey population
Overall, 1529 HCPs and 11 588 patients with T2DM were screened.
Large numbers of people were ineligible to participate because of the specific eligibility criteria (patients with T2DM on BI, HCP initiating basal insulin and/or in charge of titration education and recommendation). The final survey was undertaken by 386 HCPs and 318 patients ( Figure S1 ).
Approximately half of the total number of HCPs were PCPs ( (Table 1) . Patients who discontinued BI were younger, had lower mean bodyweight, and were more likely to be administering twice-daily insulin injections (Table S3 ). Discontinued (29) 13 (14) 99 (31) University degree 34 (22) 18 (24) 5 (6) 57 (18) Postgraduate degree 24 (16) 3 (4) 16 (18) 43 (14) Duration of T2DM, years, mean (SD) 11.4 (10.4) (14) 9 (10) 80 (25) Sulfonylureas 11 (7) 9 (12) 1 (1) 21 (7)
DPPIV inhibitors 23 (15) 4 (5) 6 (7) 33 (10) GLP-1 receptor agonists 13 (9) 7 (9) 3 (3) 23 (7) BI 106 (70) 60 (79) 67 (74) 233 (73) Rapid-acting insulin 9 (6) 5 (7) 12 (13) 26 (8) Regular human insulin 12 (8) 0 (0) 8 (9) 20 (6) NPH insulin 0 (0) 7 (9) 4 (4) 11 (3) Premix insulin 22 (14) 9 (12) 4 (4) 35 (11) Abbreviations: BI, basal insulin; DPPIV, dipeptidyl peptidase IV; GLP-1, glucagon-like peptide 1; HCP, healthcare professional; NPH, neutral protamine Hagedorn; SD, standard deviation; T2DM, type 2 diabetes.
a BI user includes both BI analogs and NPH insulin.
b France vs USA, P ≤ .01.
c Percentage expressed as percent of current BI users.
d France vs Germany, P ≤ .01.
e USA vs Germany, P < .05.
BI users felt more restricted by having to manage their diabetes, were more concerned about hypoglycaemia, and found it more difficult to integrate insulin into their daily routine (Table S3) . Given the small sample size (n = 75), and that the results for current and discontinued BI users did not generally differ, separate results for discontinued BI users have not been reported.
| Physician perspectives 3.2.1 | Key communication factors
Overall, the majority of HCPs (77%) agreed that communicating the need to increase BI dose over time was extremely/very important (75%-79%, per country). However, 45% of HCPs (USA: 53%; France: 22%; Germany: 54%) indicated that training and educating patients on titration was extremely/very challenging, given the limited time available to spend with patients. Regardless, 80% of HCPs (76%-84%) reported discussing titration at the BI initiation visit, and most HCPs (90%; 88%-92%) also felt that they could clearly explain the steps to be taken during the titration process. One-third of HCPs (33%; 30%-36%) reported discussing the anticipated time to reach glycaemic goal with patients at the initiation visit. Once the decision had been taken to initiate BI, overall one-third (33%) of HCPs reported discussing the fasting SMPG target as the goal to achieve during titration with all patients (Figure 1 ), although the main glycaemic target discussed by HCPs varied by country ( Figure S2 ). Generally, relatively few HCPs (13%) reported discussing the anticipated final insulin dose required with all patients (Figure 1 ), but this was discussed by more HCPs in Germany ( Figure S2C ).
| Self-titration and potential barriers to attainment of HbA1c targets
HCPs indicated that on average, 44% of their patients (Germany: 36%; USA: 42%; France: 55%) managed their own BI titration, and 38% of HCPs (USA: 33%; France: 57%; Germany: 28%) expressed a preference for patients to self-titrate. Overall, HCPs perceived the main barriers to target attainment in self-titrating patients to be fear of hypoglycaemia (74%), patient's hesitancy to increase the BI dose in the absence of symptoms (66%), and low patient involvement/motivation (63%; Figure 2) ; the same 3 factors were perceived as being the main barriers to target attainment in Germany and the USA, while in France, concern over weight gain was also thought to be a main concern of patients ( Figure S3 ).
| Support tools
HCPs used or recommended several educational and support tools to help patients with BI initiation and titration, including support from medical staff (telephone or office visit) (66%; 64%-66%, per country), educational pamphlets (64% overall; USA: 54%; France: 69%; Germany: 75%) and paper diaries (for SMPG results and BI dose) (61% overall;
USA: 59%; France: 51%; Germany: 75%). In the USA, France and Germany, 85%, 69% and 77% of HCPs, respectively, agreed completely or somewhat that there was a need for more effective support tools/ materials to assist with BI initiation and dose titration.
| Patient perspectives 3.3.1 | Key communication factors
Overall, 76% of patients (USA: 83%; France: 63%; Germany: 74%)
expressed some degree of confidence in being able to dose BI correctly, although many reported being unaware of the need to titrate BI dose (37% overall; USA: 42%; France: 33%; Germany: 32%).
Patient-identified factors that would increase confidence when selftitrating included further information about the HbA1c target during the titration period, the amount of time needed to achieve their goal, and the anticipated final BI dosage (Figures 3 and S4 ).
| Self-titration and potential barriers to attainment of HbA1c targets
Just over half of the total number (58% overall; USA: 53%; France: 60%; Germany: 64%) of self-titrating current BI users expressed a preference towards self-titration, while a minority (6% overall; USA: 11%; France: 3%; Germany: 2%) of current BI users with In contrast, only 38% of HCPs overall indicated that they would prefer patients to self-titrate, although this percentage was higher in France (USA: 33%; France: 57%; Germany: 28%). Reasons why HCPs preferred to manage titration themselves included that it avoided errors, provided effective control and ensured patient compliance. Target daytime test readings during the doseadaptation period FIGURE 3 Provision of information on titration factors: factors recalled by patients as being discussed with HCPs, and those factors patients consider would increase confidence in self-titration. HCP, healthcare professional Current BI users who had not reached their HbA1c target highlighted several reasons that, in their opinion, would/did contribute to not being able to increase their dose (Figures 2 and S3 ), including concerns over weight gain, perception that BI dose increase meant worsening of disease, fear of hypoglycaemia and frustration that the time to reach their HbA1c goal was too long.
Fear of hypoglycaemia
| Support tools
Patients indicated that they had used, or received, a recommendation to use a number of support tools including support from their physician (35% overall; USA: 33%; France: 33%; Germany: 40%), educational pamphlets (31% overall; USA: 36%; France: 22%; Germany: 31%) and a paper diary (for SMPG results and BI dose) (31% overall;
USA: 37%; France: 20%; Germany: 31%). 
| Potential barriers to attainment of HbA1c targets
Differences were observed between the perceived barriers to optimal titration by patients and those perceived to be patient barriers by HCPs (Figures 2 and S3 ). Frustration over time to reach goal was a factor identified by patients contributing to not reaching HbA1c target (43% overall; USA: 37%; France: 57%; Germany: 41%). However, the majority of HCPs (88%-89%) preferred that patients reached their goal safely, even if it may take longer. SMPG targets for patients who were not elderly or frail were 135 and 124 mg/dL (7.5 and 6.9 mmol/L), respectively, for PCPs and NPs in the USA, 111 and 125 mg/dL (6.2 and 6.9 mmol/L), respectively, for endocrinologists/diabetologists and nurses/CDEs in France, and 145 and 142 mg/dL (8.0 and 7.9 mmol/L), respectively, for PCPs and endocrinologists/diabetologists in Germany.
Patients were most commonly concerned about weight gain, whereas physicians identified patient fear of hypoglycaemia as the main barrier to HbA1c target achievement (Figures 2 and S3 ). In addition, lower proportions of patients than HCPs reported concerns about barriers to titration, particularly relating to fear of hypoglycaemia and low motivation and involvement. Therefore, many HCPs may overestimate patient concerns about insulin titration.
| Support tools to assist with BI initiation and titration
Although some support tools were recommended by HCPs and used by patients, the majority of HCPs (78%; USA: 85%; France: 69%; Germany: 77%) and patients (57%; USA: 49%; France: 66%;
Germany: 62%) agreed that a need remains for more effective tools to assist with BI initiation and titration. HCPs and patients identified several solutions with potential to positively impact upon the titration process, including educational tools, peer support programmes and mobile applications. Patients reported that willingness to self-titrate and confidence in self-management success would be increased by the availability and utilization of a number of these tools, including simple titration algorithms and patient support programmes (Table 2 ).
| DISCUSSION
This survey was aimed at achieving a better understanding of the barriers to optimal BI titration, in order to aid the discovery of ways to overcome these barriers in the future. Although HCPs recognized the importance of communicating the need to increase BI dose to patients, and the majority reported doing so, many patients did not recall this. The survey results are consistent with reports that patients forget a significant amount of newly learned diabetes-related information within 2 weeks of receiving it, irrespective of literacy levels, 22 and suggest that key information regarding BI titration should be reinforced at regular intervals, and by different means, to maintain patient confidence in managing their diabetes. Overall, the results of this market research survey highlight the importance of supportive tools, not only to educate and inform patients at home, but also for use during visits, to allow HCPs to have more quality time to listen to patients' questions, address any anxieties, provide reassurance, and to repeat titration instructions, if needed.
Although most HCPs recognized the importance of communicating the need to increase BI dose, 1 in 5 HCPs did not discuss this need at the initiation visit, suggesting that more effective The present survey identified a disconnect between HCPperceived and patient-perceived barriers to optimal titration. HCPs generally preferred a slow and safe approach to titration, even if it takes longer for patients to achieve their glycaemic target. Mean In conclusion, this survey, conducted in the USA, France and Germany, provides important insights into differences between HCP and patient understanding of the need to titrate BI over time to achieve optimum glycaemic control. Improving HCP-patient communication,
and providing additional educational tools and support on the titration process to increase patient confidence, both at the initiation visit and at home, may help to optimize dose titration. This in turn could reduce healthcare costs and improve treatment adherence. The results highlight the need for future research to identify appropriate support materials or tools to overcome barriers to effective titration, for both HCPs and patients, to improve glycaemic control and enhance patient outcomes.
